Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01786174 · ClinicalTrials.gov registry record · Phase 2
Gilenya in Amyotrophic Lateral Sclerosis (ALS)
A Phase 2 study, sponsored by Massachusetts General Hospital.
- Completed
- Registry status
- Phase 2
- Development phase
- 30
- Enrollment target
NCT01786174: Completed Phase 2 study, sponsored by Massachusetts General Hospital.
NCT01786174 is a Phase 2 study that has completed, run by Massachusetts General Hospital. The registered enrollment target is 30 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01786174, a Phase 2 study, has completed, sponsored by Massachusetts General Hospital.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 30 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether Gilenya, also known as fingolimod, is safe and tolerable in patients with Amyotrophic Lateral Sclerosis (ALS).
Interventions
- OTHER Placebo
- DRUG Gilenya
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2013-08 |
| Est. Completion | 2015-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01786174
The ClinicalTrials.gov registry entry for NCT01786174 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01786174 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01786174 about?
NCT01786174 is a clinical study titled "Gilenya in Amyotrophic Lateral Sclerosis (ALS)". The purpose of this study is to determine whether Gilenya, also known as fingolimod, is safe and tolerable in patients with Amyotrophic Lateral Sclerosis (ALS).
What is the current status of trial NCT01786174?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 2013-08. Estimated completion is 2015-05.
What interventions are being tested in trial NCT01786174?
The interventions under investigation include: Placebo (OTHER), Gilenya (DRUG).
Who is sponsoring clinical trial NCT01786174?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.